De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes

JB Riviere, GM Mirzaa, BJ O'Roak, M Beddaoui, D Alcantara, RL Conway, J St-Onge, JA Schwartzentruber, KW Gripp, SM Nikkel, T Worthylake, CT Sullivan, TR Ward, HE Butler, NA Kramer, B Albrecht, CM Armour, L Armstrong, O Caluseriu, C CytrynbaumBA Drolet, AM Innes, JL Lauzon, AE Lin, Grazia Verheijen - Mancini, WS Meschino, JD Reggin, AK Saggar, T Lerman-Sagie, G Uyanik, R Weksberg, B Zirn, CL Beaulieu, J Majewski, DE Bulman, M O'Driscoll, J Shendure, JM Graham, KM Boycott, WB Dobyns

Research output: Contribution to journalArticleAcademicpeer-review

612 Citations (Scopus)

Abstract

Megalencephaly-capillary malformation (MCAP) and megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndromes are sporadic overgrowth disorders associated with markedly enlarged brain size and other recognizable features(1-5). We performed exome sequencing in 3 families with MCAP or MPPH, and our initial observations were confirmed in exomes from 7 individuals with MCAP and 174 control individuals, as well as in 40 additional subjects with megalencephaly, using a combination of Sanger sequencing, restriction enzyme assays and targeted deep sequencing. We identified de novo germline or postzygotic mutations in three core components of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. These include 2 mutations in AKT3, 1 recurrent mutation in PIK3R2 in 11 unrelated families with MPPH and 15 mostly postzygotic mutations in PIK3CA in 23 individuals with MCAP and 1 with MPPH. Our data highlight the central role of PI3K-AKT signaling in vascular, limb and brain development and emphasize the power of massively parallel sequencing in a challenging context of phenotypic and genetic heterogeneity combined with postzygotic mosaicism.
Original languageUndefined/Unknown
Pages (from-to)934-+
JournalNature Genetics
Volume44
Issue number8
DOIs
Publication statusPublished - 2012

Research programs

  • EMC MGC-02-96-01

Cite this